| pubmed-article:3625706 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3625706 | lifeskim:mentions | umls-concept:C0023418 | lld:lifeskim |
| pubmed-article:3625706 | lifeskim:mentions | umls-concept:C0003392 | lld:lifeskim |
| pubmed-article:3625706 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:3625706 | lifeskim:mentions | umls-concept:C0002699 | lld:lifeskim |
| pubmed-article:3625706 | lifeskim:mentions | umls-concept:C0006948 | lld:lifeskim |
| pubmed-article:3625706 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:3625706 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:3625706 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:3625706 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:3625706 | pubmed:dateCreated | 1987-10-9 | lld:pubmed |
| pubmed-article:3625706 | pubmed:abstractText | Study of a series of aniline-substituted 9-anilinoacridines related to the antileukemic drug amsacrine showed that a 1'-carbamate group provided increased activity against the multidrug-resistant P388/ADR leukemia subline in vivo. Since activity against such resistant tumors is of great clinical significance, a series of acridine-substituted carbamate derivatives were evaluated against both wild-type and ADR/resistant P388 leukemia and the Lewis lung solid tumor in vivo. Structure-activity relationships for all three tumor lines were similar, with 3-halo-5-methyl and 3-halo-5-methoxy compounds proving the most active. This substitution pattern also provided the highest DNA binding. Such compounds (particularly the 3-chloro-5-methyl and 3-chloro-5-methoxy) have in vivo activity against wild-type P388 and Lewis lung comparable to that of the best amsacrine analogues previously developed (greater than 50% cures), as well as P388/ADR activity. This work essentially completes the development of the amsacrine series of antitumor agents. | lld:pubmed |
| pubmed-article:3625706 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3625706 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3625706 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3625706 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3625706 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3625706 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3625706 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3625706 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:3625706 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:3625706 | pubmed:author | pubmed-author:BaguleyB CBC | lld:pubmed |
| pubmed-article:3625706 | pubmed:author | pubmed-author:DennyW AWA | lld:pubmed |
| pubmed-article:3625706 | pubmed:author | pubmed-author:AtwellG JGJ | lld:pubmed |
| pubmed-article:3625706 | pubmed:author | pubmed-author:RewcastleG... | lld:pubmed |
| pubmed-article:3625706 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3625706 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:3625706 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3625706 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3625706 | pubmed:pagination | 1576-81 | lld:pubmed |
| pubmed-article:3625706 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3625706 | pubmed:meshHeading | pubmed-meshheading:3625706-... | lld:pubmed |
| pubmed-article:3625706 | pubmed:meshHeading | pubmed-meshheading:3625706-... | lld:pubmed |
| pubmed-article:3625706 | pubmed:meshHeading | pubmed-meshheading:3625706-... | lld:pubmed |
| pubmed-article:3625706 | pubmed:meshHeading | pubmed-meshheading:3625706-... | lld:pubmed |
| pubmed-article:3625706 | pubmed:meshHeading | pubmed-meshheading:3625706-... | lld:pubmed |
| pubmed-article:3625706 | pubmed:meshHeading | pubmed-meshheading:3625706-... | lld:pubmed |
| pubmed-article:3625706 | pubmed:meshHeading | pubmed-meshheading:3625706-... | lld:pubmed |
| pubmed-article:3625706 | pubmed:meshHeading | pubmed-meshheading:3625706-... | lld:pubmed |
| pubmed-article:3625706 | pubmed:meshHeading | pubmed-meshheading:3625706-... | lld:pubmed |
| pubmed-article:3625706 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3625706 | pubmed:articleTitle | Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia. | lld:pubmed |
| pubmed-article:3625706 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3625706 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:3625706 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3625706 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3625706 | lld:pubmed |
